ELIGARD 22,5 mg, poudre et solvant pour solution injectable
ENHANCE
Phase 2 small_molecule active
Quick answer
ELIGARD 22,5 mg, poudre et solvant pour solution injectable for Intermediate risk prostate cancer is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Intermediate risk prostate cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active